Researchers in a 2024 study identified what factors were involved in fertilization failure and built a nomogram (calculator) to help predict when this happens, with moderate predictive ability.
Embryoman
Researchers in a 2024 study found lower cumulative live birth rates in patients with a particular type of endometriosis (DIE and/or ovarian endometrioma) that was diagnosed using transvaginal ultrasound.
Researchers in a 2024 study compared the costs of patients with or without PGT-A, finding that patients younger than 35 may not benefit because of the higher chance of top-graded embryos being euploid anyway.
Researchers in a 2024 study measured leukocyte (white blood cell) levels in women preparing for pregnancy, and found that miscarriage risk was lower with high total leukocytes. Specific immune cells examined include monocytes, eosinophils, basophils, lymphocytes and neutrophils.
Researchers in a 2023 study compared PGT-A outcomes for patients with different diagnoses, including advanced maternal age (AMA), recurrent implantation failure (RIF), recurrent pregnancy loss (RPL) and severe male factor (SMF).
Researchers in a 2023 study found that patients with or without endometriosis have comparable live birth rates after transferring a euploid embryo, although patients may have been surgically treated (a limitation). Endometriosis patients are more likely to produce aneuploid embryos.
Researchers in a 2023 study developed a model to predict the chance of live birth after a positive β-hCG (beta-hCG), using the first measurement and a second one taken 48 hours later.
Researchers in 2023 provided evidence-based guidelines for deciding how many embryos to transfer, as prepared by ESHRE.
Laparoscopy is the gold standard for diagnosing endometriosis, but other non-surgical tests are showing potential. Here we’ll take a brief look at ReciptivaDx based on the BCL6 protein, the Endotest and DotEndo test based on a miRNA signature, the EMScore which is based on a gene expression signature, and imaging tests like ultrasound and MRI.
Researchers in a 2023 study found that day 7 euploids have the lowest ongoing pregnancy rate, when compared to day 5 and 6 euploids. These embryos were mostly poor quality.
Researchers in 2023 provide evidence-based guidelines for managing patients with unexplained infertility, as prepared by ESHRE.
Researchers in a 2023 study show that poor quality embryos have acceptable live birth rates compared to good and fair quality embryos, with only a slight increase in pregnancy loss and no differences in perinatal outcomes.
